Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-17-009213
Filing Date
2017-05-15
Accepted
2017-05-15 15:54:33
Documents
52
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q atrn20170331_10q.htm 10-Q 534280
2 EXHIBIT 31.1 ex31-1.htm EX-31.1 23040
3 EXHIBIT 31.2 ex31-2.htm EX-31.2 22550
4 EXHIBIT 32.1 ex32-1.htm EX-32.1 12229
  Complete submission text file 0001437749-17-009213.txt   3585946

Data Files

Seq Description Document Type Size
5 EXHIBIT 101.INS ptix-20170331.xml EX-101.INS 688023
6 EXHIBIT 101.SCH ptix-20170331.xsd EX-101.SCH 42955
7 EXHIBIT 101.CAL ptix-20170331_cal.xml EX-101.CAL 21079
8 EXHIBIT 101.DEF ptix-20170331_def.xml EX-101.DEF 329492
9 EXHIBIT 101.LAB ptix-20170331_lab.xml EX-101.LAB 242081
10 EXHIBIT 101.PRE ptix-20170331_pre.xml EX-101.PRE 336737
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51353 | Film No.: 17844015
SIC: 7389 Services-Business Services, NEC